Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | DUT | P33316 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14804147 | 0.81 | L3MBTL1 (0.56) | MAPTHPGDL3MBTL1MAPK1KDM4E | |
| SCHEMBL14804159 | 0.77 | SMN1; SMN2 (0.36) | MAPTHPGDL3MBTL1MAPK1ALDH1A1 | |
| SCHEMBL14804186 | 0.74 | L3MBTL1 (0.45) | MAPTHPGDL3MBTL1KDM4EKMT2A | |
| SCHEMBL13125270 | 0.74 | PLAU (0.56) | MAPTHPGDKDM4EALDH1A1KMT2A | |
| SCHEMBL5026682 | 0.74 | PLAU (0.49) | KDM4EHTT | |
| SCHEMBL5024222 | 0.73 | ESR1 (0.38) | MAPTKDM4EKMT2AMEN1DHFR | |
| SCHEMBL28538333 | 0.73 | DUT (0.43) | DUT | |
| SCHEMBL14804133 | 0.73 | MAPT (0.50) | MAPTHPGDL3MBTL1MAPK1KDM4E | |
| SCHEMBL13125218 | 0.73 | ESR1 (0.40) | MAPTL3MBTL1ALDH1A1KMT2AMEN1 | |
| SCHEMBL12243847 | 0.72 | MAPT (0.56) | MAPTHPGDL3MBTL1MAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376473-A1 | 3,4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Merck Canada Inc. (CA) | 2011-10-19 | — | — | EP | disclosed |
| US-20110237622-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2011-09-29 | — | — | US | disclosed |
| WO-2010066028-A1 | 3,4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237622-A1 | RENIN INHIBITORS | REN, ACE, ACE2 | MAPT 4520/4885HPGD 115/4885L3MBTL1 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.